Viewing Study NCT01499667


Ignite Creation Date: 2025-12-25 @ 12:40 AM
Ignite Modification Date: 2025-12-29 @ 10:09 AM
Study NCT ID: NCT01499667
Status: TERMINATED
Last Update Posted: 2014-08-08
First Post: 2011-08-18
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Sponsor: Novartis Pharmaceuticals
Organization: